All In Biotech

Drug Trial Radar · NCT07184645

A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 0.3% OPA-15406 Foam to the Vehicle in Children With Atopic Dermatitis in Combination With an Open-label, Uncontrolled Trial to Evaluate the Safety and Efficacy of 0.3% and 1% OPA-15406 Foam in Infants Under 2 Years of Age and Children With Atopic Dermatitis (Phase 3 Trial)

Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 198 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

198

Planned (sponsor's estimate)

Start

Sep 2025

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Sponsor type
Industry
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 months, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the superiority of 0.3% OPA-15406 foam to the vehicle in children with atopic dermatitis (AD)

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • OPA-15406Drug

    0.3% foam or 1% foam, topical, twice daily, for 8 weeks

  • VehicleDrug

    vehicle, topical, twice daily, for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Success rate in Investigator's Global Assessment (IGA)Time frame: Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sumire Dermatology Clinic

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.